Atlas Trials

Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma

Clinical trial NCT01995669 · COMPLETED

Trial details

NCT number
NCT01995669
Sponsor
M.D. Anderson Cancer Center
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Grade 3a Follicular LymphomaRecurrent Follicular LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaRefractory Follicular LymphomaRefractory Marginal Zone LymphomaRefractory Small Lymphocytic Lymphoma
Start date
2014-05-27
Primary completion
2023-01-23
Enrollment
66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.